Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Samsung Bioepis Clears Up Second EU Bevacizumab Application

Market Entry Also Confirmed For Aybintio Biosimilar

Executive Summary

Samsung Bioepis last week received a second positive opinion recommending granting a pan-European marketing authorization for a biosimilar bevacizumab product. The Korean firm spoke to Generics Bulletin detailing the rationale.

You may also be interested in...



Samsung Bioepis Breaks Down Biosimilar Experiences In Europe And US

Samsung Bioepis reiterated that the US pharma market is “the most fragmented and the most complicated market in the world” as it discussed its biosimilar fortunes in Europe.

Merck & Co Puts A Date On Spinning Off Biosimilars

Merck & Co has disclosed more precise details around plans to spin off its more mature products, including biosimilars, into a new publicly traded company.

Mystery Surrounds Second Samsung Bioepis Avastin Biosimilar

Samsung Bioepis is lining up two biosimilar bevacizumab products in the EU, after the EMA’s CHMP recommended the company’s Onbevzi product months after approval for Aybintio.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB150439

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel